Screener
Turn Therapeutics Inc. TTRX Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Turn Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Turn Therapeutics Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-054490
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net gain from change in fair value of derivative liability instrument | 697,561 | - |
| Amortization of deferred offering cost | (477,647) | - |
| Interest income | 49,679 | 5,165 |
| Other income | 5,578 | 51,285 |
| Total other income | 275,171 | 56,450 |
| NET LOSS | $(970,972) | $(328,547) |
| Basic and diluted net loss per common share | $(0.03) | $(0.01) |
| Weighted-average common shares outstanding, basic and diluted | 29,476,002 | 26,956,217 |
Item 1. Condensed Consolidated Financial Statements (Unaudited).
FAQ
- What is Turn Therapeutics Inc.'s net income?
- Turn Therapeutics Inc. (TTRX) reported net income of -$970.97K in Q1 2026.
- How has Turn Therapeutics Inc.'s net income changed year-over-year?
- Turn Therapeutics Inc.'s net income decreased by 195.5% year-over-year, from -$328.55K to -$970.97K.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Turn Therapeutics Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude